Predictors of Persistent Peanut Allergy at Age 5 Years
Early Life Origins of the Food Allergy Epidemic: Predictors of Persistent Peanut Allergy at Age 5 Years
The purpose of this study is to determine if avoidance of peanut by children with positive allergy testing to peanut in the first 5 years of life increases the likelihood of developing a persistent peanut allergy by age 5 years. To answer this question, the investigators need to determine which children with positive allergy testing to peanut have reactions after eating peanut (allergic to peanut) and which are able to tolerate eating peanut (not allergic).
The investigators plan to conduct double-blind placebo-controlled peanut challenges (gold standard for peanut allergy diagnosis) for CHILD study (http://www.canadianchildstudy.ca) participants who had positive skin prick testing to peanut at ages 1, 3 or 5 years (in other words, children who are sensitized to peanut, but may or may not be allergic to peanut) and who are avoiding peanut without ever having had a reaction or whose history suggests that they may have outgrown a known peanut allergy. These challenges will not change a child's ability to tolerate peanut, but will determine if children who are avoiding peanut are allergic to peanut (and need to continue avoiding peanut) or clinically tolerant to peanut (and may continue to eat peanut after passing the challenge).
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Introduction:
Food allergy has reached epidemic levels in Canada and peanut allergy is the most prevalent and one of the more persistent food allergies among Canadian children and adults. Avoidance or later introduction of peanut has been proposed as a possible cause of the increased rates of peanut sensitization and allergy. Although delaying the introduction of peanut into children's diets is no longer recommended, many parents continue to worry about introducing peanut and some will not introduce peanut into their child's diet without a negative skin prick test to peanut. However, some children who have never had a reaction to peanut can eat and tolerate peanut despite being sensitized (having a positive skin prick test) to peanut.
The purpose of this study is to determine if avoidance of peanut by children with positive skin prick testing to peanut in the first 5 years of life increases the likelihood of developing a persistent peanut allergy by age 5 years. To answer this question, the investigators need to determine which children with positive skin prick testing to peanut have reactions after eating peanut (allergic to peanut) and which are able to tolerate eating peanut (not allergic).
Specific Objectives:
- To conduct double-blind placebo-controlled peanut challenges among 5-year-old children who are sensitized to and avoiding peanut, to determine if they are allergic to peanut (and need to continue avoiding peanut) or clinically tolerant to peanut (and may continue to eat peanut after passing the challenge)
- To determine the relative risk of developing peanut allergy among peanut-sensitized children who have been eating versus avoiding peanut.
Challenge Procedure:
Double-blind placebo-controlled food challenges are the gold standard clinical practice for diagnosis of food allergies, and involve the child undergoing separate challenges to the food and to a placebo so that the child, parents, and physicians and nurses administering the challenge are masked regarding which challenge is to the food and which is to the placebo. All children will undergo challenges to both peanut and placebo, in a randomized order. These challenges will not change a child's ability to tolerate peanut, but will determine if children who are avoiding peanut are allergic to peanut (and need to continue avoiding peanut) or clinically tolerant to peanut (and may continue to eat peanut after passing the challenge).
The challenges will be conducted in clinical units set up for food challenges, by a research nurse and a pediatric allergist with expertise and experience in managing food allergies and oral food challenges. Each child will undergo a challenge to peanut on one day and a challenge to placebo on another day. The peanut will be concealed in a vehicle, such as a shake or smoothie. One of the challenges will contain peanut and the concealing vehicle and the other challenge will contain only the vehicle. The challenge foods will be prepared by a team member who is not otherwise involved in the challenges. A study worker not involved in the challenges will also be in charge of randomizing the two challenges to peanut or placebo and of decoding the challenge food identity after both challenges are completed. The children, their families, the research nurse and the pediatric allergist will not know whether the challenge food contains the peanut or the placebo until both challenges have been completed. This procedure helps to distinguish symptoms that occur due to anxiety (equally likely to occur in both the peanut and placebo challenges) and those that are a reaction to peanut (occur only during the peanut challenge).
Children who do not develop any symptoms of anaphylaxis (e.g. hives, swelling, trouble breathing, vomiting, abdominal pain or changes in their level of consciousness) during the challenge or the 2-hour observation period after the challenge will have passed the challenge and will be considered clinically tolerant; they will be encouraged to continue eating peanut at home at least once per week. Children who develop any of these symptoms during the challenge containing peanut will be considered allergic, especially if symptoms did not occur during the challenge containing only the vehicle.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Challenge Inclusion Criteria:
CHILD study participants will be eligible for challenge if they
- Have completed their 5-year-old CHILD Study visit
- Are or have been sensitized to peanut i.e. have had a positive skin prick test (wheal diameter at least 2 mm greater than the negative control) and/or allergen-specific IgE level (>0.35 kU/L) to peanut at their 1-, 3- and/or 5-year-old CHILD study visit
- Are not eating peanut. Children who eat less than 8-10 g of peanut per month or who eat only foods that 'may contain' traces of peanut will still be eligible for inclusion.
Challenge Exclusion Criteria:
CHILD study participants will be ineligible for challenge if
- They have never had a positive skin prick test or allergen-specific IgE level to peanut
- They are eating 8-10 g of peanut at least once per month, despite having had a positive skin prick test or allergen-specific IgE level to peanut
- Their family has declined to participate
- They have a peanut skin prick test wheal size >8mm and/or a peanut-specific IgE >15 kU/L and a history suggestive of an IgE-mediated allergic reaction to peanut.
- They have a history of anaphylaxis to peanut or a challenge-proven diagnosis of peanut allergy within the past 1-2 years.
- They have uncontrolled asthma or any other contraindication to performing a DBPC food challenge on the day of challenge. These children may be rescheduled if their asthma control improves.
Blood Draw Inclusion Criteria:
CHILD study participants will be eligible for blood draw if they
- Have completed their 5-year-old CHILD Study visit
- Are or have been sensitized to peanut i.e. have had a positive skin prick test (wheal diameter at least 2 mm greater than the negative control) and/or allergen-specific IgE level (>0.35 kU/L) to peanut at their 1-, 3- and/or 5-year-old CHILD study visit
Blood Draw Exclusion Criteria:
CHILD study participants will be ineligible for blood draw if
- They have never had a positive skin prick test or allergen-specific IgE level to peanut
- Their family has declined to participate
Immunological analyses of the blood samples are underway now that the 2 sites participating in this portion of the study (University of Manitoba and University of British Columbia) have completed their challenges. Challenges were halted in the spring.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Avoiding and possibly allergic to peanut
Challenge Group: Children with positive skin prick testing to peanut who are avoiding peanut will undergo a double-blind placebo-controlled peanut challenge (gold standard for peanut allergy diagnosis) if their allergy evaluation suggests that they have a good chance of not being allergic to peanut.
Children who pass the challenge are not allergic to peanut.
Children who react during the challenge are allergic to peanut and will continue to avoid peanut.
|
Children who are avoiding peanut will be gradually introduced to smoothies containing and not containing peanut, to see if they are able to tolerate eating peanut.
This challenge does not change a child's ability to tolerate peanut, but will determine which children avoiding peanut are allergic to peanut and which children are not allergic and may begin eating peanut.
Other Names:
|
|
Not allergic to peanut
Comparison Group: Children with positive skin prick testing to peanut who are eating and tolerating peanut are not clinically allergic to peanut and may continue eating peanut.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical tolerance to peanut (passing a peanut challenge and eating peanut regularly)
Time Frame: Age 5 years
|
Clinical tolerance to peanut (passing a peanut challenge and eating peanut regularly)
|
Age 5 years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Elinor Simons, MD PhD MSc, Section of Allergy, Department of Pediatrics & Child Health, University of Manitoba
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- B2015:052
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Allergy to Peanut
-
NCT01966640CompletedAllergy to Egg | Allergy to Peanut
-
NCT01996774Completed
-
NCT05695261RecruitingPeanut Hypersensitivity | Peanut Allergy | Food Allergy | Food Allergy Peanut | Peanut-Induced Anaphylaxis | Allergy, Peanut
-
NCT02149719CompletedIgE Mediated Peanut Allergy
-
NCT04200989WithdrawnFood Allergy Peanut
-
NCT04984876Terminated
-
NCT03881696CompletedPeanut Allergy | Multi-food Allergy
-
NCT06554691Active, not recruitingAllergy;Food | Food Allergy | Food Allergy in Children | Food Allergy Peanut | Tree Nut Allergies | Oral Immunotherapy for Food Allergy
-
NCT03907397CompletedPeanut Allergy | Food Allergy
-
NCT01781637CompletedPeanut Allergy | Food Allergy
Clinical Trials on Double-blind placebo-controlled peanut challenge
-
NCT02365168Completed
-
NCT06997432Not yet recruiting
-
NCT03897088Completed
-
NCT04700449CompletedModerate to Severe Ulcerative Colitis
-
NCT06406114RecruitingDrug Hypersensitivity | Drug-Induced Anaphylaxis | Antibiotic Allergy | Drug Allergy | Beta Lactam Adverse Reaction | Cephalosporin Allergy | Cephalosporin Reaction
-
NCT00847613Completed
-
NCT00960440Completed
-
NCT01543178CompletedIrritable Bowel Syndrome With Diarrhea